A New Clinical Instrument for Estimating the Ambulatory Status after Irradiation for Malignant Spinal Cord Compression.
ambulatory status
irradiation
malignant spinal cord compression
prognostic instrument
prospective trials
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Aug 2022
07 Aug 2022
Historique:
received:
13
06
2022
revised:
01
08
2022
accepted:
05
08
2022
entrez:
12
8
2022
pubmed:
13
8
2022
medline:
13
8
2022
Statut:
epublish
Résumé
Estimating post-treatment ambulatory status can improve treatment personalization of patients irradiated for malignant spinal cord compression (MSCC). A new clinical score was developed from data of 283 patients treated with radiotherapy alone in prospective trials. Radiotherapy regimen, age, gender, tumor type, interval from tumor diagnosis to MSCC, number of affected vertebrae, other bone metastases, visceral metastases, time developing motor deficits, ambulatory status, performance score, sensory deficits, and sphincter dysfunction were evaluated. For factors with prognostic relevance in the multivariable logistic regression model after backward stepwise variable selection, scoring points were calculated (post-radiotherapy ambulatory rate in % divided by 10) and added for each patient. Four factors (primary tumor type, sensory deficits, sphincter dysfunction, ambulatory status) were used for the instrument that includes three prognostic groups (17-21, 22-31, and 32-37 points). Post-radiotherapy ambulatory rates were 10%, 65%, and 97%, respectively, and 2-year local control rates were 100%, 75%, and 88%, respectively. Positive predictive values to predict ambulatory and non-ambulatory status were 97% and 90% using the new score, and 98% and 79% using the previous instrument. The new score appeared more precise in predicting non-ambulatory status. Since patients with 32-37 points had high post-radiotherapy ambulatory and local control rates, they may not require surgery.
Identifiants
pubmed: 35954490
pii: cancers14153827
doi: 10.3390/cancers14153827
pmc: PMC9367288
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : European Regional Development Fund (Interreg Deutschland-Danmark program)
ID : 094 -1.1-18
Références
J Neurosurg Spine. 2010 Sep;13(3):324-8
pubmed: 20809724
Spine (Phila Pa 1976). 2010 Oct 15;35(22):E1221-9
pubmed: 20562730
Cancers (Basel). 2022 Feb 28;14(5):
pubmed: 35267568
BMC Cancer. 2017 Dec 04;17(1):818
pubmed: 29202720
Ann Neurol. 1978 Jan;3(1):40-51
pubmed: 655653
J Clin Oncol. 2010 Aug 1;28(22):3597-604
pubmed: 20606090
BMC Cancer. 2019 Nov 29;19(1):1163
pubmed: 31783816
J Clin Oncol. 2019 Jan 1;37(1):61-71
pubmed: 30395488
Spine (Phila Pa 1976). 2021 Apr 15;46(8):550-558
pubmed: 33273445
JAMA. 2019 Dec 3;322(21):2084-2094
pubmed: 31794625
J Clin Oncol. 2011 Aug 1;29(22):3072-7
pubmed: 21709187
Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):e861-8
pubmed: 21277114
Eur J Cancer. 1994;30A(3):396-8
pubmed: 8204366
Nat Rev Clin Oncol. 2010 Oct;7(10):590-8
pubmed: 20808299
J Clin Oncol. 2016 Feb 20;34(6):597-602
pubmed: 26729431
Lancet. 2005 Aug 20-26;366(9486):643-8
pubmed: 16112300
Int J Radiat Oncol Biol Phys. 2020 Mar 15;106(4):780-789
pubmed: 31812719
Acta Neurochir (Wien). 1990;107(1-2):37-43
pubmed: 2096606
Int J Radiat Oncol Biol Phys. 2011 Apr 1;79(5):1503-6
pubmed: 20605351
Lancet Oncol. 2005 Jan;6(1):15-24
pubmed: 15629272
Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):905-8
pubmed: 18436390